Latest Videos
Revumenib’s FDA Approval and Clinical Implications
Revumenib’s FDA Approval and Clinical Implications
Dr Chmielowski on the Rationale for Investigating Oncolytic Viruses in Melanoma
Dr Chmielowski on the Rationale for Investigating Oncolytic Viruses in Melanoma
Key Takeaways: The Current Landscape and Future of CML Care
Key Takeaways: The Current Landscape and Future of CML Care
DIssecting the Current Treatment Landscape for R/R Follicular Lymphoma
DIssecting the Current Treatment Landscape for R/R Follicular Lymphoma
Dr Hoda on Characterizing HR–Positive, HER2-Low, -Ultralow, and -Null Metastatic Breast Cancer
Dr Hoda on Characterizing HR–Positive, HER2-Low, -Ultralow, and -Null Metastatic Breast Cancer
Navigating Challenges in Second- and Third-Line AML Therapy
Navigating Challenges in Second- and Third-Line AML Therapy
Dr Ghobadi on the Efficacy and Safety of WU-CART-007 in R/R T-ALL and LBL
Dr Ghobadi on the Efficacy and Safety of WU-CART-007 in R/R T-ALL and LBL
Dr Fenske on the Omission of ASCT in Mantle Cell Lymphoma After First CR and uMRD
Dr Fenske on the Omission of ASCT in Mantle Cell Lymphoma After First CR and uMRD
Dr Lotan on the Benefits and Complications Associated With Radical Cystectomy in BCG-Unresponsive NMIBC
Dr Lotan on the Benefits and Complications Associated With Radical Cystectomy in BCG-Unresponsive NMIBC
ASC4FIRST Trial & Asciminib New FDA Approval: Evaluating Asciminib in First-Line CML Treatment
ASC4FIRST Trial & Asciminib New FDA Approval: Evaluating Asciminib in First-Line CML Treatment
Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
Dr Dronca on the FDA Approval of Subcutaneous Nivolumab in Solid Tumors
Dr Dronca on the FDA Approval of Subcutaneous Nivolumab in Solid Tumors
Dr Eckfeldt on the Treatment Paradigm and Current Challenges in MDS
Dr Eckfeldt on the Treatment Paradigm and Current Challenges in MDS
Dr Goldsberry on PARP Inhibitor Selection in Advanced Ovarian Cancer
Dr Goldsberry on PARP Inhibitor Selection in Advanced Ovarian Cancer
Dr Riess on the Investigation of Ivonescimab in Advanced NSCLC
Dr Riess on the Investigation of Ivonescimab in Advanced NSCLC
Dr Lotan on the Future Research Directions in BCG-Unresponsive NMIBC
Dr Lotan on the Future Research Directions in BCG-Unresponsive NMIBC
Dr Huppert on Survival Outcomes of Patients With Metastatic Breast Cancer and Leptomeningeal Disease
Dr Huppert on Survival Outcomes of Patients With Metastatic Breast Cancer and Leptomeningeal Disease
Dr Niravath on Durvalumab, Trastuzumab, and Pertuzumab in HER2-Enriched Breast Cancer
Dr Niravath on Durvalumab, Trastuzumab, and Pertuzumab in HER2-Enriched Breast Cancer
Dr Dasari on the Evolving Treatment Paradigm in mCRC
Dr Dasari on the Evolving Treatment Paradigm in mCRC
Dr Geyer on the Efficacy of Perioperative Atezolizumab Plus Chemotherapy in Stage II/III TNBC
Dr Geyer on the Efficacy of Perioperative Atezolizumab Plus Chemotherapy in Stage II/III TNBC
Biomarker Consortium Videos
Predictive Biomarkers for Treatment With Amivantamab Plus Lazertinib Among EGFR-Mutated NSCLC in the Post-Osimertinib Setting: Analysis of Tissue IHC and ctDNA NGS
Predictive Biomarkers for Treatment With Amivantamab Plus Lazertinib Among EGFR-Mutated NSCLC in the Post-Osimertinib Setting: Analysis of Tissue IHC and ctDNA NGS
How Do You Explain Adjuvant Therapy in NSCLC?
How Do You Explain Adjuvant Therapy in NSCLC?
Dr Schneider on Diagnostic Testing Turnaround Times in Lung Cancer
Dr Schneider on Diagnostic Testing Turnaround Times in Lung Cancer
Dr Pellini on Comprehensive Genomic Profiling and Repeat Biomarker Testing in NSCLC
Dr Pellini on Comprehensive Genomic Profiling and Repeat Biomarker Testing in NSCLC
Tissue and Plasma-Based Mechanisms of Resistance to First-Line Osimertinib in EGFR-Mutant NSCLC: A Multi-Institutional Cohort
Tissue and Plasma-Based Mechanisms of Resistance to First-Line Osimertinib in EGFR-Mutant NSCLC: A Multi-Institutional Cohort
Dr Kim on NSCLC Treatment Selection Based on Biomarker Testing Results
Dr Kim on NSCLC Treatment Selection Based on Biomarker Testing Results
Real-World Testing and Treatment Patterns Among Patients With Stage IV NSCLC: A Retroscpective Observational Study
Real-World Testing and Treatment Patterns Among Patients With Stage IV NSCLC: A Retroscpective Observational Study
Dietrich and Shiller on the Importance of Oncology Reflex Testing
Dietrich and Shiller on the Importance of Oncology Reflex Testing
Contemporary Biomarker Testing Rates in Both Early and Advanced NSCLC: Results From the MYLUNG Pragmatic Study
Contemporary Biomarker Testing Rates in Both Early and Advanced NSCLC: Results From the MYLUNG Pragmatic Study
How Do You Explain Neoadjuvant Therapy in NSCLC?
How Do You Explain Neoadjuvant Therapy in NSCLC?
Rationale and Insights: Testing for MET Alterations in NSCLC
Rationale and Insights: Testing for MET Alterations in NSCLC
	 Navigating Frontline Treatment Options in BRAF V600E-Mutant NSCLC
Navigating Frontline Treatment Options in BRAF V600E-Mutant NSCLC
Dr Rodriguez on Treating Patients With Lung Cancer Harboring Multiple Actionable Mutations
Dr Rodriguez on Treating Patients With Lung Cancer Harboring Multiple Actionable Mutations
AE Monitoring and Management Strategies for BRAF V600E-Targeted Therapies in NSCLC
AE Monitoring and Management Strategies for BRAF V600E-Targeted Therapies in NSCLC
Florez Focuses on Patient-Centered NSCLC Biomarker Testing
Florez Focuses on Patient-Centered NSCLC Biomarker Testing
Navigating Frontline Treatment Options in NSCLC with METex14 Mutations
Navigating Frontline Treatment Options in NSCLC with METex14 Mutations
Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing
Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing
Rationale and Insights: Testing for BRAF Mutations in NSCLC
Rationale and Insights: Testing for BRAF Mutations in NSCLC
Dr Olazagasti on the Use of Biomarker Testing in Lung Cancer
Dr Olazagasti on the Use of Biomarker Testing in Lung Cancer
When Should Patients With NSCLC be Referred to Thoracic Surgeons in Specialized Centers of Care?
When Should Patients With NSCLC be Referred to Thoracic Surgeons in Specialized Centers of Care?
AE Monitoring and Management Strategies for MET Inhibitors in NSCLC
AE Monitoring and Management Strategies for MET Inhibitors in NSCLC

All Oncology News